title: Treatment of Helicobacter pylori infection 2016.
abstract: Many interesting articles have been published from different parts of the world over the last year assessing various issues around Helicobacter pylori eradication therapy. This article will address the published literature over the last year pertaining to the topic of treatment of H. pylori infection. The main themes that emerge are assessing the efficacy of standard triple therapy, as well as exploring new first-line treatments, mainly optimized nonbismuth-containing and bismuth-containing quadruple therapies with some promising data also emerging on dual therapy. There was also considerable progress in investigating antibiotic resistance rates with much more data emerging from varied parts of the world compared to recent years. Advances in the use of adjunctive therapies, especially probiotic therapies have also been made. Undoubtedly, the eradication of H. pylori remains a worthwhile goal to alleviate the burden of diseases caused by the complications of this infection, including dyspepsia, peptic ulcer disease, and gastric cancer.
authors.affiliation: Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.|Department Of Gastroenterology, Tallaght Hospital/Trinity College, Dublin, Ireland.
authors.forename: Anthony
authors.initials: A
authors.lastname: O'Connor
authors.affiliation: Medizinische Klinik II, Klinikum Aschaffenburg, Academic Teaching Hospital of the University of Würzburg, Aschaffenburg, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Fischbach
authors.affiliation: Gastroenterology Unit, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
authors.forename: Javier P
authors.initials: JP
authors.lastname: Gisbert
authors.affiliation: Department Of Gastroenterology, Tallaght Hospital/Trinity College, Dublin, Ireland.
authors.forename: Colm
authors.initials: C
authors.lastname: O'Morain
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination / Q000379:methods; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D015995:Prevalence; D019936:Probiotics / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors
keywords: concomitant therapy; hybrid therapy; peptic ulcer disease; resistance; sequential therapy